开发与验证一种预测黑色素瘤患者前哨淋巴结活检后无复发生存和黑色素瘤特异性生存的新模型:一项国际性回顾性多中心分析
该国际回顾性多中心分析在开发队列4071例和外部验证队列4822例黑色素瘤患者中构建了包含6个预后因素的列线图模型,预测5年无复发生存和黑色素瘤特异性生存。开发队列AUC分别为0.80和0.81,外部验证AUC分别为0.73和0.76,校准良好。作者认为该工具可能对高危黑色素瘤辅助治疗的临床决策有重要意义。
要点
- 模型含6个因素:前哨淋巴结状态、Breslow厚度、溃疡、年龄、原发部位、最大转移灶直径。
- 开发队列预测无复发生存AUC 0.80,黑色素瘤特异性生存AUC 0.81。
- 外部验证AUC分别为0.73和0.76,校准良好。
核心结论
- 作者认为该预测模型和列线图准确预测了患者个体5年无复发生存和黑色素瘤特异性生存的风险概率,可能对高危黑色素瘤辅助治疗的临床决策有重要意义。
研究设计与样本
- 国际性回顾性多中心分析,开发队列纳入1997年10月29日至2013年11月11日在四个欧洲黑色素瘤中心(德国柏林;荷兰阿姆斯特丹和鹿特丹;波兰华沙)接受前哨淋巴结活检的13岁以上确诊原发性黑色素瘤患者4071例。
- 外部验证队列纳入1997年1月30日至2013年12月12日在澳大利亚黑色素瘤研究所(悉尼)接受前哨淋巴结活检的原发性黑色素瘤患者4822例。
主要发现
- 开发队列4071例中女性2075例(51%)、男性1996例(49%),前哨淋巴结阳性889例(22%)、阴性3182例(78%);中位随访4.8年(IQR 2.3-7.8)。
- 验证队列4822例中女性1965例(41%)、男性2857例(59%),前哨淋巴结阳性891例(18%)、阴性3931例(82%);中位随访5.0年(IQR 2.2-8.9)。
- 开发队列5年无复发生存率为73.5%(95%CI 72.0-75.1),5年黑色素瘤特异性生存率为86.5%(95%CI 85.3-87.8)。
- 验证队列5年无复发生存率为66.1%(95%CI 64.6-67.7),5年黑色素瘤特异性生存率为83.3%(95%CI 82.0-84.6)。
- 最终模型含6个预后因素:前哨淋巴结状态、Breslow厚度、溃疡存在、前哨淋巴结活检时年龄、原发肿瘤部位、最大前哨淋巴结转移灶最大直径。
关键数值与推荐
- 开发队列中模型预测无复发生存的AUC为0.80(95%CI 0.78-0.81),预测黑色素瘤特异性生存的AUC为0.81(95%CI 0.79-0.84)。
- 外部验证显示两种结局校准良好,AUC分别为0.73(95%CI 0.71-0.75)和0.76(95%CI 0.74-0.78)。
临床怎么用
- 作者认为该预测模型和列线图可用于预测患者个体5年无复发生存和黑色素瘤特异性生存的风险概率,可能对高危黑色素瘤辅助治疗的临床决策有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of adjuvant systemic treatment for patients with high-risk melanomas necessitates accurate staging of disease. However, inconsistencies in outcomes exist between disease stages as defined by the American Joint Committee on Cancer (8th edition). We aimed to develop a tool to predict patient-specific outcomes in people with melanoma rather than grouping patients according to disease stage. METHODS: Patients older than 13 years with confirmed primary melanoma who underwent sentinel lymph node biopsy (SLNB) between Oct 29, 1997, and Nov 11, 2013, at four European melanoma centres (based in Berlin, Germany; Amsterdam and Rotterdam, the Netherlands; and Warsaw, Poland) were included in the development cohort. Potential predictors of recurrence-free and melanoma-specific survival assessed were sex, age, presence of ulceration, primary tumour location, histological subtype, Breslow thickness, sentinel node status, number of sentinel nodes removed, maximum diameter of the largest sentinel node metastasis, and Dewar classification. A prognostic model and nomogram were developed to predict 5-year recurrence-free survival on a continuous scale in patients with stage pT1b or higher melanomas. This model was also calibrated to predict melanoma-specific survival. Model performance was assessed by discrimination (area under the time-dependent receiver operating characteristics curve [AUC]) and calibration. External validation was done in a cohort of patients with primary melanomas who underwent SLNB between Jan 30, 1997, and Dec 12, 2013, at the Melanoma Institute Australia (Sydney, NSW, Australia). FINDINGS: The development cohort consisted of 4071 patients, of whom 2075 (51%) were female and 1996 (49%) were male. 889 (22%) had sentinel node-positive disease and 3182 (78%) had sentinel node-negative disease. The validation cohort comprised 4822 patients, of whom 1965 (41%) were female and 2857 (59%) were male. 891 (18%) had sentinel node-positive disease and 3931 (82%) had sentinel node-negative disease. Median follow-up was 4·8 years (IQR 2·3-7·8) in the development cohort and 5·0 years (2·2-8·9) in the validation cohort. In the development cohort, 5-year recurrence-free survival was 73·5% (95% CI 72·0-75·1) and 5-year melanoma-specific survival was 86·5% (85·3-87·8). In the validation cohort, the corresponding estimates were 66·1% (64·6-67·7) and 83·3% (82·0-84·6), respectively. The final model contained six prognostic factors: sentinel node status, Breslow thickness, presence of ulceration, age at SLNB, primary tumour location, and maximum diameter of the largest sentinel node metastasis. In the development cohort, for the model's prediction of recurrence-free survival, the AUC was 0·80 (95% CI 0·78-0·81); for prediction of melanoma-specific survival, the AUC was 0·81 (0·79-0·84). External validation showed good calibration for both outcomes, with AUCs of 0·73 (0·71-0·75) and 0·76 (0·74-0·78), respectively. INTERPRETATION: Our prediction model and nomogram accurately predicted patient-specific risk probabilities for 5-year recurrence-free and melanoma-specific survival. These tools could have important implications for clinical decision making when considering adjuvant treatments in patients with high-risk melanomas. FUNDING: Erasmus Medical Centre Cancer Institute.
引用
- Stassen RC, Maas CCHM, van der Veldt AAM, et al. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis. Lancet Oncol. 2024. PMID: 38547894. doi:10.1016/S1470-2045(24)00076-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。